CEOP-R regimen: Difference between revisions

	WikiDoc Resources for CEOP-R regimen
Articles
Most recent articles on CEOP-R regimen Most cited articles on CEOP-R regimen Review articles on CEOP-R regimen Articles on CEOP-R regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on CEOP-R regimen Images of CEOP-R regimen Photos of CEOP-R regimen Podcasts & MP3s on CEOP-R regimen Videos on CEOP-R regimen
Evidence Based Medicine
Cochrane Collaboration on CEOP-R regimen Bandolier on CEOP-R regimen TRIP on CEOP-R regimen
Clinical Trials
Ongoing Trials on CEOP-R regimen at Clinical Trials.gov Trial results on CEOP-R regimen Clinical Trials on CEOP-R regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on CEOP-R regimen NICE Guidance on CEOP-R regimen NHS PRODIGY Guidance FDA on CEOP-R regimen CDC on CEOP-R regimen
Books
Books on CEOP-R regimen
News
CEOP-R regimen in the news Be alerted to news on CEOP-R regimen News trends on CEOP-R regimen
Commentary
Blogs on CEOP-R regimen
Definitions
Definitions of CEOP-R regimen
Patient Resources / Community
Patient resources on CEOP-R regimen Discussion groups on CEOP-R regimen Patient Handouts on CEOP-R regimen Directions to Hospitals Treating CEOP-R regimen Risk calculators and risk factors for CEOP-R regimen
Healthcare Provider Resources
Symptoms of CEOP-R regimen Causes & Risk Factors for CEOP-R regimen Diagnostic studies for CEOP-R regimen Treatment of CEOP-R regimen
Continuing Medical Education (CME)
CME Programs on CEOP-R regimen
International
CEOP-R regimen en Espanol CEOP-R regimen en Francais
Business
CEOP-R regimen in the Marketplace Patents on CEOP-R regimen
Experimental / Informatics
List of terms related to CEOP-R regimen

VisualWikitext

Revision as of 13:24, 11 March 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords: CEOP Regimen; Cyclophosphamide/Epirubicin/Vincristine/Prednisone

Overview

CEOP-R regimen refers to an immunochemotherapy regimen consisting of cyclophosphamide, Epirubicin, vincristine (Oncovin), prednisone and rituximab used to treat both indolent and aggressive forms of Diffuse large B-cell lymphoma.^[1]==Regimen== C – Cyclophosphamide

E – Epirubicin

O – Vincristine (Oncovin)

P – Prednisone

R – Rituximab

Indications

Diffuse large B-cell lymphoma^[1]

References

↑ ^1.0 ^1.1 Li Y, Yimamu M, Wang X, Zhang X, Mao M, Fu L; et al. (2014). "Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression". Int J Hematol. 99 (1): 79–86. doi:10.1007/s12185-013-1472-z. PMID 24258714.

[pmid24258714-1] 1.0 ^1.1 Li Y, Yimamu M, Wang X, Zhang X, Mao M, Fu L; et al. (2014). "Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression". Int J Hematol. 99 (1): 79–86. doi:10.1007/s12185-013-1472-z. PMID 24258714.

[1]

@@ Line 3: / Line 3: @@
 {{CMG}}; {{AE}} {{AV}}
-{{SK}} Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone regimen
+{{SK}} CEOP Regimen; Cyclophosphamide/Epirubicin/Vincristine/Prednisone
 ==Overview==
-{{PAGENAME}} refers to an immunochemotherapy regimen consisting of [[rituximab]], [[cyclophosphamide]], [[doxorubicin |hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride)]], [[vincristine|vincristine (Oncovin)]] and [[prednisone]] used to treat both indolent and aggressive forms of [[non-Hodgkin lymphoma]].<ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate =  | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref>
+{{PAGENAME}} refers to an immunochemotherapy regimen consisting of  [[cyclophosphamide]], [[Epirubicin]], [[vincristine|vincristine (Oncovin)]], [[prednisone]] and [[rituximab]] used to treat both indolent and aggressive forms of [[Diffuse large B-cell lymphoma]].<ref name="pmid24258714">{{cite journal| author=Li Y, Yimamu M, Wang X, Zhang X, Mao M, Fu L et al.| title=Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression. | journal=Int J Hematol | year= 2014 | volume= 99 | issue= 1 | pages= 79-86 | pmid=24258714 | doi=10.1007/s12185-013-1472-z | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24258714  }} </ref>==Regimen==
-==Regimen==
-[[Rituximab|{{button|R – Rituximab}}]]
 [[Cyclophosphamide|{{button|C – Cyclophosphamide}}]]
-[[Doxorubicin|{{button|H – Doxorubicin (Hydroxydaunomycin)}}]]
+[[Epirubicin|{{button|E – Epirubicin}}]]
 [[Vincristine|{{button|O – Vincristine (Oncovin)}}]]
@@ Line 19: / Line 16: @@
 [[Prednisone|{{button|P – Prednisone}}]]
+[[Rituximab|{{button|R – Rituximab}}]]
 ==Indications==
-* [[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma, untreated]]<ref>{{Cite journal | doi = 10.1056/NEJMoa011795 | issn = 1533-4406 | volume = 346 | issue = 4 | pages = 235–242 | last = Coiffier | first = Bertrand | coauthors = Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard, Felix Reyes, Pierre Lederlin, Christian Gisselbrecht | title = CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | journal = The New England Journal of Medicine | date = 2002-01-24 | pmid = 11807147 }}</ref>
+* [[Diffuse large B-cell lymphoma]]<ref name="pmid24258714">{{cite journal| author=Li Y, Yimamu M, Wang X, Zhang X, Mao M, Fu L et al.| title=Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression. | journal=Int J Hematol | year= 2014 | volume= 99 | issue= 1 | pages= 79-86 | pmid=24258714 | doi=10.1007/s12185-013-1472-z | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24258714  }} </ref>
-* [[Mantle cell lymphoma]]<ref>{{Cite journal | doi = 10.1056/NEJMoa1200920 | issn = 1533-4406 | volume = 367 | issue = 6 | pages = 520–531 | last = Kluin-Nelemans | first = H. C. | coauthors = E. Hoster, O. Hermine, J. Walewski, M. Trneny, C. H. Geisler, S. Stilgenbauer, C. Thieblemont, U. Vehling-Kaiser, J. K. Doorduijn, B. Coiffier, R. Forstpointner, H. Tilly, L. Kanz, P. Feugier, M. Szymczyk, M. Hallek, S. Kremers, G. Lepeu, L. Sanhes, J. M. Zijlstra, R. Bouabdallah, P. J. Lugtenburg, M. Macro, M. Pfreundschuh, V. Procházka, F. Di Raimondo, V. Ribrag, M. Uppenkamp, M. André, W. Klapper, W. Hiddemann, M. Unterhalt, M. H. Dreyling | title = Treatment of older patients with mantle-cell lymphoma | journal = The New England Journal of Medicine | date = 2012-08-09 | pmid = 22873532 }}</ref>
 ==References==
 {{Reflist|2}}
 [[Category:Chemotherapy regimens]]

CEOP-R regimen: Difference between revisions

Revision as of 13:24, 11 March 2015

Overview

Indications

References

Navigation menu